Bain Capital and Cinven cleared to relaunch offer for Stada Arz

11 July 2017

Bain Capital and Cinven, through their Nidda Healthcare unit, have been cleared by German regulators to submit a renewed binding voluntary public takeover offer for all outstanding shares of Stada Arzneimittel (SAZ: Xetra), further to its previous bid failing to gain adequate shareholder support.

The German Federal Financial Supervisory Authority (BaFin) has approved the exemption from the one-year exclusion period for the submission of a renewed offer, which began after the termination of the published on June 27, unsuccessful takeover offer, with immediate effect. The offer documentation will be published at short notice.

Offer upped from 66.00 euros to 66.25 and acceptance threshold cut to 63%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK